List view / Grid view
4 March 2016 | By Victoria White
Victoza (liraglutide) was studied over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events...
3 March 2016 | By Victoria White
New findings show that Xultophy is cost-effective versus current insulin intensification treatment options for the treatment of people in the UK with type 2 diabetes...
23 February 2016 | By Victoria White
This NDA submission is based on data from two Phase 3 studies of insulin glargine and lixisenatide in patients with with type 2 diabetes...
18 February 2016 | By Victoria White
A new study has found that pioglitazone may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes...
29 January 2016 | By Victoria White
SWITCH 2 is the first of two trials comparing the safety and efficacy of Tresiba (insulin degludec) and insulin glargine in patients with type 2 diabetes...
26 January 2016 | By Victoria White
The FDA has accepted a sNDA for Jardiance (empagliflozin) based on cardiovascular risk reduction data from the EMPA-REG OUTCOME trial...
17 December 2015 | By Victoria White
The trial investigated the efficacy and safety of semaglutide compared with sitagliptin after 56 weeks of treatment in people with type 2 diabetes...
17 December 2015 | By Victoria White
The FDA has approved Basaglar for the treatment of adult and paediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus...
10 December 2015 | By Victoria White
Faster-acting insulin aspar is an investigational mealtime insulin developed by Novo Nordisk for the control of blood sugar levels in adults with type 1 and type 2 diabetes...
4 December 2015 | By Victoria White
Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes...
New data from a completed Phase 3 trial show Lilly’s Trulicity (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering haemoglobin A1c (A1C) from baseline after 24 weeks of treatment.
2 December 2015 | By Victoria White
Novo Nordisk has released new data that shows Victoza (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose cotransporter 2 inhibitors...
18 November 2015 | By Victoria White
Merck and Novapharm have announced a joint venture in Algeria to produce Merck’s diabetes and high blood pressure treatments for the Algerian market...
16 November 2015 | By Victoria White
New research shows socio-cultural factors including time pressure, commuting time and where you live play significant roles in diabetes vulnerability...
6 November 2015 | By Victoria White
Sotagliflozin is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 which could be a potential treatment option for people with diabetes...
